Pfizer Consumer Healthcare Launches the World's First Non-Prescription Brand for Erectile Dysfunction
It is estimated that erectile problems affect up to 21 percent of men in the U.K. - equivalent to 4.3 million individuals. With Viagra Connect® now available as a non-prescription medication, millions of men in the country can more actively manage an aspect of their health that can have a significant impact on their relationships.
This first-of-its-kind launch included an extensive training program for pharmacists to help them assess and recommend treatment. In addition, because ED is often caused by underlying cardiovascular disease, the screening assessment plays a critical role in engaging men with health care providers.
Ian Read: Contributions to Improving Human Health
Albert Bourla: Breakthroughs that Change Patients' Lives
Ushering in a New Era of Pfizer R&D Productivity
Advancing Our Leading JAK Science
Overcoming Therapy-Resistant Disease
Tackling Respiratory Syncytial Virus (RSV) Through Breakthrough Science and Technology
Catalyzing Innovations in Global Health
Contributing to the UN Sustainable Development Goals
Supporting Digital Health Start-Ups
Improving the Health of Women and Their Families